Disc Medicine, Inc. Common Stock

Day range

$74.80 – $78.03

Open

$74.80

Prev close

$74.51

Volume

403.16K

Market cap

$3.31B

Shares out

38.39M

P/E

—

P/S

—

P/B

5.13

P/FCF

—

ROE

-38.2%

ROA

-33.5%

Debt/Equity

0.09

Div yield

0.00%

As of Oct 23, 2026

• Preliminary resultsOct 22, 2026

  On October 20, 2026, the Company announced that its preliminary unaudited cash, cash equivalents and marketable securities as of September 30, 2026 were approximately $682.8 million. The Company has not yet completed its quarter-end financial close process ... This estimate ... is preliminary, has not been audited and is subject to change.

• Clinical trial resultsOct 19, 2026

  Bitopertin demonstrated additional quality of life benefits vs. placebo, including improved Patient Global Impression of Change (PGIC) score (p<0.0001) and Patient Global Impression of Severity (PGIS) score (p<0.0001).

• Clinical trial resultsSep 10, 2026

  On September 9, 2026, the Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase 2, multi-center, open-label RESTORE-PV trial enrolled 40 adult participants with PV, including 20 participants in Cohort A and 20 participants in Cohort B.

• Credit facilityJun 30, 2026

  On June 25, 2026, Disc Medicine, Inc. entered into a First Amendment to Loan Agreement to the Loan and Security Agreement dated as of November 6, 2024 among the Company, the lender party thereto and Hercules Capital, Inc., as administrative agent and collateral agent for the purpose of extending the periods during which future Advances may be drawn down.

• Regulatory decisionFeb 27, 2026

  the Company received a complete response letter from the U.S. Food and Drug Administration ("FDA") on February 13, 2026 with respect to the Company's New Drug Application for bitopertin for the treatment of erythropoietic protoporphyria and X-linked protoporphyria.

Days to cover

12.8

Short interest

7.27M

Avg volume

568.32K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
  positiveGlobeNewswire Inc.· Oct 20, 2026
• Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
  positiveGlobeNewswire Inc.· Oct 18, 2026
• Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
  negativeGlobeNewswire Inc.· Oct 5, 2026
• Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
  negativeGlobeNewswire Inc.· Sep 22, 2026
• Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
  negativeGlobeNewswire Inc.· Sep 12, 2026